Evidence map›Paper›PMID 35386474›Full record

ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2022

The neuroinflammatory marker sTNFR2 relates to worse cognition and tau in women across the Alzheimer's disease spectrum.

Rachel A Bernier, Sarah J Banks, Matthew S Panizzon, Murray J Andrews, Emily G Jacobs, Douglas R Galasko, Alyx L Shepherd, Katerina Akassoglou, Erin E Sundermann, Alzheimer's Disease Neuroimaging Initiative

Open access · goldAbstract read
In one paragraph

Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Sex differences inFrontiers in dementia · 2025
    Pooled it
  3. Review
  4. Astrocytes in aging.Neuron · 2025
    Review
  5. Review
  6. Article
  7. Review
  8. Dementia, infections and vaccines: 30 years of controversy.Aging clinical and experimental research · 2023
    Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Rachel A BernierDepartment of Neuroscience University of California, San Diego San Diego California USA.ORCID https://orcid.org/0000-0002-2759-9186
Sarah J BanksDepartment of Neuroscience University of California, San Diego San Diego California USA.
Matthew S PanizzonDepartment of Psychiatry University of California, San Diego San Diego California USA.
Murray J AndrewsDepartment of Neuroscience University of California, San Diego San Diego California USA.
Emily G JacobsDepartment of Psychological and Brain Sciences University of California, Santa Barbara Santa Barbara California USA.
Douglas R GalaskoDepartment of Neuroscience University of California, San Diego San Diego California USA.
Alyx L ShepherdDepartment of Neuroscience University of California, San Diego San Diego California USA.
Katerina AkassoglouGladstone UCSF Center for Neurovascular Brain Immunology San Francisco California USA.
Erin E SundermannDepartment of Psychiatry University of California, San Diego San Diego California USA.
Alzheimer's Disease Neuroimaging Initiative
University of San Diego · USUniversity of California San Diego · USGladstone Institutes · USUniversity of California, Santa Barbara · US

Funding

Project 1U19AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI Duygu Tosun-Turgut · 2016 to 2026
$226.7M
Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Neurovascular Interactions: Mechanisms, imaging, therapeutic potentialR35NS097976 · NINDS · J. DAVID GLADSTONE INSTITUTES · PI AKASSOGLOU, KATERINA · 2016 to 2023
$11.1M
Fibrinogen and vascular cognitive impairment: mechanisms, imaging, therapeuticsRF1AG064926 · NIA · J. DAVID GLADSTONE INSTITUTES · PI AKASSOGLOU, KATERINA, ELLISMAN, MARK H · 2019 to 2019
$4.5M
Sex-specific cognitive expression and risk in preclinical Alzheimer's diseaseR01AG066088 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BANKS, SARAH · 2019 to 2023
$3.9M
NIA NIH HHS R01 AG066088NIA NIH HHS RF1 AG064926NIA NIH HHS U01 AG024904NIA NIH HHS U19 AG024904NINDS NIH HHS R35 NS097976
6 · The paper itself

Abstract

Introduction: Despite women showing greater Alzheimer's disease (AD) prevalence, tau burden, and immune/neuroinflammatory response, whether neuroinflammation impacts cognition differently in women versus men and the biological basis of this impact remain unknown. We examined sex differences in how cerebrospinal fluid (CSF) neuroinflammation relates to cognition across the aging-mild cognitive impairment (MCI)-AD continuum and the mediating role of phosphorylated tau (p-tau) versus other AD biomarkers. Methods: Participants included 284 individuals from the Alzheimer's Disease Neuroimaging Initiative study. CSF neuroinflammatory markers included interleukin-6, tumor necrosis factor α, soluble tumor necrosis factor receptor 2 (sTNFR2), and chitinase-3-like protein 1. AD biomarkers were CSF p-tau Results: We found a sex-by-sTNFR2 interaction on Mini-Mental State Examination and Clinical Dementia Rating-Sum of Boxes. Higher levels of sTNFR2 related to poorer cognition in women only. Among biomarkers, only p-tau Discussion: Women may be more susceptible than men to the adverse effects of sTNFR2 on cognition with a potential etiological link with tau to these effects.

Indexed as

agingAlzheimer's diseasemagnetic resonance imagingneuroinflammationphosphorylated tausex differences

Identifiers

PMID35386474
PMCPMC8973901
OpenAlexW4225963810

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.